Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
20
DAWN Quote, Financials, Valuation and Earnings
Last price:
$10.03
Seasonality move
:
-34.56%
Day range:
$10.11 - $10.62
52-week range:
$5.64 - $13.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.75x
P/B ratio:
2.41x
Volume:
1.4M
Avg. volume:
2.4M
1-year change:
14.46%
Market cap:
$1.1B
Revenue:
$158.2M
EPS (TTM):
-$1.04
Analysts' Opinion
-
Consensus RatingDay One Biopharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.75, Day One Biopharmaceuticals, Inc. has an estimated upside of 119.38% from its current price of $10.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $10.37.
Fair Value
-
According to the consensus of 6 analysts, Day One Biopharmaceuticals, Inc. has 119.38% upside to fair value with a price target of $22.75 per share.
DAWN vs. S&P 500
-
Over the past 5 trading days, Day One Biopharmaceuticals, Inc. has underperformed the S&P 500 by -10.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Day One Biopharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Day One Biopharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Day One Biopharmaceuticals, Inc. reported revenues of $53.7M.
Earnings Growth
-
Day One Biopharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Day One Biopharmaceuticals, Inc. reported earnings per share of -$0.21.
Enterprise value:
626.4M
EV / Invested capital:
1.41x
Price / LTM sales:
6.75x
EV / EBIT:
--
EV / Revenue:
3.96x
PEG ratio (5yr expected):
-27.93x
EV / Free cash flow:
-5.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$141M
Return On Assets:
-20.19%
Net Income Margin (TTM):
-67.85%
Return On Equity:
-22.98%
Return On Invested Capital:
-22.84%
Operating Margin:
-51.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $131.2M | $158.2M | $29.2M | $53.7M | |
| Gross Profit | -$383K | $125.8M | $141M | $26.2M | $47.6M | |
| Operating Income | -$206.1M | -$217.3M | -$127.8M | -$65.3M | -$27.5M | |
| EBITDA | -$205.7M | -$215.2M | -$124M | -$64.6M | -$26.5M | |
| Diluted EPS | -$2.36 | -$1.04 | -$1.04 | -$0.65 | -$0.21 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $289.4M | $347.9M | $375.3M | $562.3M | $485.1M | |
| Total Assets | $289.8M | $349.1M | $376M | $582.8M | $507.8M | |
| Current Liabilities | $8.7M | $16.6M | $29.5M | $73.5M | $60.5M | |
| Total Liabilities | $8.7M | $17M | $29.5M | $80M | $66.7M | |
| Total Equity | $281.1M | $332M | $346.5M | $502.8M | $441.2M | |
| Total Debt | $16K | $408K | -- | $2.6M | $2.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$146.9M | -$78.1M | -$103.8M | -$30M | -$14.1M | |
| Cash From Investing | $128.4M | -$231M | $174.6M | -$269.6M | $167.5M | |
| Cash From Financing | $164M | $203.3M | $1.2M | $1.9M | $471K | |
| Free Cash Flow | -$147.1M | -$97.4M | -$107.6M | -$31.4M | -$14.1M | |
DAWN
Sector
Market Cap
$1.1B
$25.6M
Price % of 52-Week High
78.56%
50%
Dividend Yield
0%
0%
Shareholder Yield
-0.13%
-1.62%
1-Year Price Total Return
14.46%
-18.97%
Beta (5-Year)
--
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.27
200-day SMA
Buy
Level
$8.12
Bollinger Bands (100)
Buy
Level
7.86 - 11.04
Chaikin Money Flow
Sell
Level
-30.1M
20-day SMA
Sell
Level
$11.28
Relative Strength Index (RSI14)
Sell
Level
42.58
ADX Line
Sell
Level
21.47
Williams %R
Buy
Level
-87.2549
50-day SMA
Sell
Level
$10.67
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
43.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.2739)
Buy
CA Score
(Annual)
Level (0.2702)
Sell
Beneish M-Score
(Annual)
Level (-1.6065)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.8248)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.
Stock Forecast FAQ
In the current month, DAWN has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DAWN average analyst price target in the past 3 months is $22.75.
-
Where Will Day One Biopharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Day One Biopharmaceuticals, Inc. share price will rise to $22.75 per share over the next 12 months.
-
What Do Analysts Say About Day One Biopharmaceuticals, Inc.?
Analysts are divided on their view about Day One Biopharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Day One Biopharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Day One Biopharmaceuticals, Inc.'s Price Target?
The price target for Day One Biopharmaceuticals, Inc. over the next 1-year time period is forecast to be $22.75 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DAWN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Day One Biopharmaceuticals, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DAWN?
You can purchase shares of Day One Biopharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Day One Biopharmaceuticals, Inc. shares.
-
What Is The Day One Biopharmaceuticals, Inc. Share Price Today?
Day One Biopharmaceuticals, Inc. was last trading at $10.03 per share. This represents the most recent stock quote for Day One Biopharmaceuticals, Inc.. Yesterday, Day One Biopharmaceuticals, Inc. closed at $10.37 per share.
-
How To Buy Day One Biopharmaceuticals, Inc. Stock Online?
In order to purchase Day One Biopharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DAWN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DAWN
Sector
P/E ratio
--
23.22x
PEG ratio
-27.93x
-0.01x
P/B ratio
2.41x
1.80x
Price / LTM sales
6.75x
1.53x
Growth Metrics
DAWN
Sector
Revenue growth
83.92%
3.44%
Earnings growth
68.21%
11.15%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.15
-$0.19
Profitability
DAWN
Sector
Profitability FY 2025
$141M
$2.4M
Return on invested capital
-22.84%
-33.43%
Return on assets
-20.19%
-29.79%
Return on equity
-22.98%
-39.31%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
May
5
Estimated Next Earnings Date
May
26
Balance Sheet
DAWN
Sector
Total cash
$441.1M
$24.1M
Short term investments
$406.8M
$23.8M
Total assets
$507.8M
$70.2M
Long term debt
$2.6M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
